Trial Profile
A Phase 1b, Open-Label, Multiple-Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AK002 in Patients with Peanut Allergy
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jun 2018
Price :
$35
*
At a glance
- Drugs Lirentelimab (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors Allakos
- 04 Jun 2018 New trial record